Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Peptide Vaccines and Leukine in Neoplasms
NCT05475106Phase 1Recruiting
- Sponsor
- Instituto de Medicina Regenerativa
- Start
- May 2022
- Primary completion
- Nov 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen peptide vaccine in malignant neoplasm, sponsored by Instituto de Medicina Regenerativa. Primary endpoints: Change from Baseline in White Blood Cell count at 12 months and Change from Baseline in Red Blood Cell count at 12 months. Started May 2022; status: recruiting.
02
Drugs
personalized neoantigen peptide vaccine
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT05475106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475106.